Table 1.
Grouped first- and second-line treatments, including HSCT, by age group.
| Age categories | N (%) | 20–59 years | 60–69 years | 70–79 years | 80–84 years | 85+ years |
|---|---|---|---|---|---|---|
| First-line regimens | N = 1,888 | N = 432 (22.9%) | N = 393 (20.8%) | N = 535 (28.3%) | N = 289 (15.3%) | N = 239 (12.7%) |
| Full R-CHOP a | 826 (44) | 210 (49) | 238 (61) | 261 (49) | 90 (31) | 27 (11) |
| Incomplete R-CHOP b | 337 (18) | 78 (18) | 70 (18) | 110 (21) | 62 (21) | 17 (7) |
| Other anthracycline c | 271 (14) | 115 (27) | 45 (11) | 68 (13) | 30 (10) | 13 (5) |
| Non-anthracycline d | 162 (9) | 8 (2) | 16 (4) | 39 (7) | 46 (16) | 53 (22) |
| Only radiotherapy e | 47 (2) | 2 (0.5) | 3 (0.8) | 6 (1) | 12 (4) | 24 (10) |
| No chemo/radiotherapy | 245 (13) | 19 (4) | 21 (5) | 51 (10) | 49 (17) | 105 (44) |
| Second-line regimens | N = 252 | N = 82 | N = 71 | N = 71 | N = 24 | N = 4 |
| Platinum-based | 178 (71) | 64 (78) | 56 (79) | 45 (63) | 12 (50) | 1 (25) |
| Cytarabine-based f | 8 (3) | 4 (5) | 3 (4) | 1 (1) | 0 (0) | 0 (0) |
| Anthracycline-based | 17 (7) | 8 (10) | 2 (3) | 6 (8) | 1 (4) | 0 (0) |
| Bendamustine-based | 8 (3) | 0 (0) | 0 (0) | 1 (1) | 5 (21) | 2 (50) |
| Palliative | 19 (8) | 1 (1) | 4 (6) | 11 (15) | 3 (13) | 0 (0) |
| Other g | 22 (9) | 5 (6) | 6 (8) | 7 (10) | 3 (13) | 1 (25) |
| % of start first line | 16% | 20% | 19% | 15% | 11% | 4% |
| % of diagnosed | 13% | 19% | 18% | 13% | 8% | 2% |
| Refractory h (%first line) | 111 (7) | 34 (8) | 35 (9) | 32 (7) | 8 (4) | 2 (2) |
| Relapsed h (%first line) | 142 (9) | 49 (12) | 36 (10) | 39 (8) | 16 (7) | 2 (2) |
| HSCT i | N = 92 | N = 66 | N = 24 | N = 2 | N = 0 | N = 0 |
| Autologous | 82 | 56 | 24 | 2 | 0 | 0 |
| Allogeneic | 10 | 8 | 2 | 0 | 0 | 0 |
≥ 6 cycles (≥ 4 if Ann Arbor stage = I).
Incomplete if < 6 cycles or < 4 if Ann Arbor stage = I or if CHOP without R.
R-ACVBP, RA-CHOP, CHOEP, COEP, CODOX-M, HyperCVAD, CHOP-like, DHAP, DHAP-like, ICE, platinum-containing, R-MAD.
R-monotherapy, R-CVP, bendamustine-containing, experimental and palliative regimens.
Within 12 weeks from diagnosis, 6 additional patients received only RT > 12 weeks from diagnosis.
Not containing platinum, anthracyclines, or bendamustine.
Includes CNS-directed therapy, only gemcitabine-containing, experimental therapies.
Presumed refractory of relapsed when starting the 2nd line of therapy < or >12 weeks from last administration of the first-line treatment.
Hematopoietic stem cell transplantation, after 1st, 2nd, or further lines of therapy.